
Please try another search
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Name | Age | Since | Title |
---|---|---|---|
Nicholas Fernandez | 41 | 2025 | Independent Director |
Chris Kim | 65 | 2022 | CEO & Chairman |
Sang-jin Lee | 57 | 2025 | Head of Research & Development and Member of Scientific Advisory Board |
Byong Chul Yoo | 53 | 2025 | Chief Science Officer & Member of Scientific Advisory Board |
Ji Yeon Baek | 53 | 2025 | Independent Director |
Eun Sook Lee | 61 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review